Pivotal Life Sciences related stories
All articles and analysis
DermBiont lands $28m Series A2DermBiont, a developer of targeted topical therapeutics that address the root causes of skin diseases, has raised $28 million in Series A2 financing.
Evommune pulls in $83m Series AEvommune, Inc., a private R&D company and innovation engine in chronic inflammation, has secured $83 million in Series A financing.
Fusion Pharmaceuticals goes public, expects to raise $212mFusion Pharmaceuticals, a Hamilton, Ontario-based cancer radiotherapeutics company, has priced its IPO on the NASDAQ at US$17 per share.
- VC-backed Fusion Pharmaceuticals seeks $125m from IPO: report
Canadian cancer radiotherapeutics specialist Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) from its initial public offering on Nasdaq.
- Rallybio inks $145m Series B
New Haven, Connecticut-based Rallybio, a biopharmaceutical company, has closed $145 million in Series B funding.
VC-backed Karuna goes publicKaruna Therapeutics, a biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, has raised $89.2 million for its IPO after pricing its over 5.5 million shares at $16 per share. The stock began trading June 28, 2019 on the NASDAQ under the ticker symbol "KRTX." Goldman Sachs and Citigroup are the lead underwriters. Karuna's pre-IPO backers included ARCH Venture Partners, Fidelity Management & Research Co, Eventide Asset Management, Pivotal bioVenture Partners, Partner Fund Management, Wellcome Trust, Sands Capital and Alexandria Venture Investments.
Canadian VC begins 2019 with heft as top Q1 deals raise $667 mlnAfter nine straight years of growth, Canada’s venture capital market showed no signs of slowing down in early 2019. The top 10 first-quarter VC financings drew $667 million from VC funds. While that’s down 28 percent from the $923 million raised by the top 10 deals a year earlier, it exceeds first-quarter results in other recent years. The estimate is based on PE Hub Canada’s list of the largest rounds announced from January through March, supplemented by preliminary data from Refinitiv. It suggests that despite increasing market uncertainty, trends in early 2019 reflect many of the same factors that drove soaring Canadian VC investment activity last year.
- Fusion Pharmaceuticals racks up $105 mln Series B
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company, has raised $105 million in Series B financing. Varian and OrbiMed led the round with participation from other investors that included Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital, Healthcap, Adams Street Partners, Johnson & Johnson Innovation – JJDC Inc, TPG Biotech, Seroba Life Sciences, Genesys Capital and FACIT. In conjunction with the funding, Deepak Khuntia, senior vice president and chief medical officer at Varian, Chau Q. Khuong, a partner at OrbiMed and Heather Preston, a managing director at Pivotal bioVenture Partners, will join Fusion’s board of directors.
Radiotherapeutics pioneer Fusion lands $140 mln in Series B roundFusion Pharmaceuticals, a cancer radiotherapeutics specialist, raised $140 million (US$105 million) in a Series B financing, one of the largest Canadian biotech deals on record. Varian Medical Systems, a Silicon Valley oncology business, co-led the round with New York healthcare investment giant OrbiMed. They were joined by new and existing investors, including Canadian life sciences venture firm Genesys Capital. Fusion's platform uses technology to link targeting molecules with short-path alpha medical isotopes to effectively kill cancer cells. “It’s essentially a smart bomb for cancer,” Genesys Managing Director Damian Lamb told PE Hub Canada.